Read in another language

Guide

Can Eye Rejuran Help My Dark Circles, Hollows, or Fine Lines?

Eye Rejuran (Rejuran i) may help fine lines and skin texture around the eyes. It is not established for true hollows, pigment dark circles or puffiness.

Author
Written and reviewed by Kwang Yeon Kim, MD and Jee Hoon Ju, MD
Published:

Eye Rejuran (Rejuran i) is a low-viscosity polynucleotide injectable that may improve fine lines and skin texture around the eyes, but it is not established as a treatment for true hollowing, pigment-type dark circles or puffiness. The randomized eye-area trial used in this guide enrolled 27 people and gave three treatments two weeks apart, so the evidence is small. The decision rule is to classify the concern first and choose the treatment second.

This is a composite scene, not a real patient. A traveler preparing for a Seoul consultation has saved three phrases for one worry: dark circles, tear troughs, crepey skin. A clinic menu offers Eye Rejuran and a full-face version of it. Neither label says whether the darkness is pigment, visible vessels, a shadow or swelling. A good consultation separates those findings before any injectable is discussed.

Six-step diagram: classify the finding, screen history, confirm the product, plan sessions, judge over weeks, and report lasting swelling.

Questions and answers

What exactly is Eye Rejuran?

Eye Rejuran is the everyday Korean name for Rejuran i, an injectable gel of purified polynucleotides (PN) taken from salmon and made at a lower viscosity than standard Rejuran (PharmaResearch brochure). The brochure positions it for crow's feet and thin skin. That positioning does not make every under-eye concern a suitable target.

A sealed white Rejuran i box held in one hand in front of stacked product boxes

The brand covers several formulations. The brochure lists Rejuran i and standard Rejuran, often called Rejuran Healer, as 2% PN, with lower viscosity for i. HB Plus contains 1% PN, hyaluronic acid and a local anesthetic, and a thicker product is aimed at scars. Ask for the exact name on the sealed box.

It is also different from PDRN serums and creams. Evidence does not transfer between an injection and a topical product, or between different formulations (SEME review 2026). Japan's health ministry once published a recall of two Rejuran-branded topical serums over their packaging. That notice concerned cosmetics and did not involve the injectable (MHLW).

Are dark circles, hollows, bags and fine lines the same problem?

No. They are different findings that often appear together, and each needs its own assessment. Dark circles alone can come from pigment, visible blood vessels, structural shadow or a mix of these (periorbital hyperpigmentation review). The 2023 posts said one treatment could solve eye wrinkles, hollowing and dark circles together. The evidence supports treating them as separate findings, with the examination organizing the plan.

What you noticeLikely main causeWhere a PN skin-quality injection stands
Fine lines, dry or crepey surfaceThin skin and texture changeReasonable to discuss; evidence is small
Brown discolorationPigmentNot established; needs a pigment assessment
Blue or purple tintVessels showing through thin skinNot established
Shadow in a groove (tear trough)Structural hollowingDoes not replace volume; separate assessment
Bags or puffinessFluid or structural changeNo established benefit; a reason to pause first

The last column is a starting point for a conversation with a physician. It does not diagnose anything.

What does the evidence show for the eye area?

The evidence supports modest improvement in selected skin-quality measures, and it is thin. A randomized, double-blind, split-face trial enrolled 27 participants and compared PN with a hyaluronic acid filler around the eyes (J Dermatol Treat trial). Subjective improvement scores did not differ significantly between the two sides, and neither did improvement in dermal density. Its measurements suggest possible gains in items such as pore appearance. That is a reason to discuss fine lines and texture. It does not prove general rejuvenation.

For hollowing, clinicians answering a current patient question separate skin quality from structural volume loss, which is expert opinion and not trial data (RealSelf Q&A). A skin-quality injection is not established as volume replacement. If the main finding is a groove, the filler guide covers that assessment.

For dark circles, a whitening effect is not established. A 2026 pilot of facial PN treatment in 19 adults with atopic dermatitis found no significant change in melanin index (Dermatologic Therapy pilot).

The familiar story about collagen and regeneration rests largely on laboratory work, and clinical results do not confirm every step of it (SEME review 2026).

Were Rejuran studies retracted, and what does that mean?

Yes, two separate trials were retracted, for different reasons. A crow's-feet trial comparing PN with hyaluronic acid was retracted in 2016 because its funding and conflict-of-interest disclosures were incorrect (JKMS notice). A different trial, comparing polycaprolactone and PN fillers for crow's feet, was retracted on March 16, 2026 after the comparator material was found to be misidentified, which put its reliability in question (Wiley notice).

The retractions do not prove that PN treatment fails. They do mean those trials cannot be used as support. A 2026 systematic review of eye-area PN still includes the trial retracted in March, so its headline totals and response percentages should not be quoted as clean evidence (ASJ Open Forum review). This guide uses neither trial's figures.

Why would a clinic use Eye Rejuran over the whole face?

A full-face Eye Rejuran is a clinic protocol and has not been validated as a separate indication. When I wrote about this in 2023, I described a full-face protocol given with a Dermashine injector as this clinic's own know-how. I also wrote that the lower viscosity lets the gel spread well in areas of thin skin.

Sealed Rejuran syringes in clear trays lying in front of white product boxes

That reasoning is plausible, but the evidence reviewed for this guide did not include a controlled comparison of this exact full-face protocol. The manufacturer's Korean instructions list the intended use as temporary improvement of adult facial wrinkles (Rejuran IFU). They do not establish glow, lifting or volume as outcomes.

Before agreeing, ask which sealed product is used, on which area, by which delivery method, and whether anything is mixed with it.

Is Eye Rejuran painless, and will I have bumps?

No. Pain and visible bumps are both possible, whatever the method. The 2023 posts called the treatment painless and said bumps could be avoided. A 15-participant split-face study recorded injection pain and local reactions with conventional Rejuran i (Aesthetic Plastic Surgery 2025). The Australian distributor lists papules, redness and swelling as temporary changes after treatment (Rejuran ANZ).

Close crop of closed eyes with rows of small raised injection bumps beneath both eyes

Numbing cream can be part of the plan, but it does not make treatment pain-free. Lower viscosity alone does not prove less pain or faster settling either.

In the original posts, I injected the eye area by hand. The posts described a Dermashine injector for the full-face protocol. No controlled comparison of that injector with hand injection was found, so neither method can be called better for comfort or bumps. Method and anesthesia are planned for each patient.

Can polynucleotides make under-eye puffiness worse?

Nobody can give a reliable rate, and swelling that persists or worsens should be examined instead of waited out. Temporary swelling, redness and papules are documented after treatment. The available studies are small and short, so they cannot rule out uncommon or delayed problems.

Do not assume a worsening look is a normal healing phase, and do not accept a diagnosis or copy a treatment regimen found online. First contact the clinic that treated you. If you have left Korea, see a physician in person where you are.

Seek emergency medical care immediately for any vision change, unusual or severe pain, white, gray or blue skin near the injection site, or sudden weakness, facial drooping or difficulty speaking. Breathing difficulty or throat swelling also requires immediate emergency care. Do not wait for a routine clinic reply (FDA).

There is no fixed deadline for bumps to settle and no universal waiting time before a flight. The flight planning guide covers timing.

How many sessions do I need, and when should I judge it?

There is no established universal schedule. The three sessions two weeks apart in the 27-person trial are a research design and should not be read as a prescription. The distributor also describes planning as individual (Rejuran ANZ).

In December 2023 I wrote that the number of sessions and the interval should be planned around each patient's condition, because under-eye skin is thin and dry. In November 2023 I wrote that some patients returned for treatment once a month. That describes clinic practice at the time. No evidence-based monthly maintenance schedule exists.

Do not judge the treatment on the same day. An immediate glow cannot show tissue change, and studies assess outcomes over weeks.

In the same December post I wrote that careful home care is important, and then recommended a procedure for skin that is already dry. Dermatology guidance puts moisturizer and gentle skincare first, and dryness that persists deserves a diagnosis (AAD).

Who should not have Eye Rejuran, and who needs extra screening?

Some people should not have this treatment under the product label, and others need screening first. The manufacturer's Korean instructions for use prohibit treatment during pregnancy or breastfeeding, in minors, and in skin that is inflamed or infected (Rejuran IFU). The same label lists further contraindications to screen for:

Physician consultation desk with a laptop
  • allergic disease or hypersensitivity to a component
  • autoimmune disease, sarcoidosis or other granulomatous disease, and Osler's endocarditis
  • certain medications, including NSAIDs, antiplatelet agents, anticoagulants and immunosuppressants
  • sites filled recently, or sites holding a permanent filler

Do not stop a prescribed medication to qualify for treatment. Tell the physician everything you take, any heart or immune condition you have, and which fillers you have had and where.

Tell the physician about any fish allergy or previous injection reaction before booking. An ophthalmology education page advises against PN injections in people with fish or shellfish allergy (EyeWiki). Do not assume purification makes the product safe for you. Eligibility must follow the current product label, so ask the clinic to check your history against the current full version.

Existing puffiness and earlier eyelid surgery also belong in that conversation. Sensitive or atopic skin is not a proven indication. The 2026 pilot in atopic dermatitis had no control group and ongoing background treatment.

Is Rejuran FDA approved, and is Korean approval the same thing?

No United States FDA approval of a Rejuran injectable could be verified, and Korean approval applies to Korea only. Rejuran did not appear on the FDA's page of approved dermal fillers when checked, though that is not a full database search (FDA).

Status by region:

  • Korea: the manufacturer's instructions list Rejuran, Rejuran i and Rejuran s under device permit 14-825 (Rejuran IFU).
  • European Union: the manufacturer reports CE MDR certification for three Rejuran products. The certificate itself was not inspected (PharmaResearch).
  • Australia: the register has an active Class III entry for Rejuran as an animal-derived dermal tissue material. That entry does not by itself identify the Rejuran i model (TGA).
  • Japan, mainland China, Thailand and the United Kingdom: current model-specific authorization was not established. Availability in a clinic is not approval.

The posts cited Class IV device status as a sign of safety and absorption. A device class describes a finished product and its intended use. It does not grade the safety of an ingredient.

Which claims in the 2023-2024 posts go beyond the evidence?

Several claims in the clinic's 2023-2024 posts exceed the evidence reviewed for this guide. Beyond those already covered above:

  • Safety: the posts called PN harmless, free of foreign material and closest to human DNA. It is a manufactured, animal-derived gel placed in tissue, and biological similarity does not predict one person's reaction.
  • Biology: the posts placed new collagen in both the epidermis and the dermis. The proposed activity concerns dermal fibroblasts and the matrix around them (SEME review 2026).
  • Comparisons: the posts called filler and botulinum toxin unnatural. Those treatments have different purposes, and results depend on selection and technique.
  • Wider claims: lifting, volume, acne scars, less sebum and prevention of aging are not established for this protocol.
  • Promotion: rankings, endorsements and offers ran through the posts. Popularity does not show suitability, and Korean law restricts exaggerated medical advertising (Medical Service Act, Article 56). This guide leaves them out.

Some points in the posts hold up: PN comes from salmon, Rejuran i is the lower-viscosity version, cold dry air worsens dryness, and session plans should be individual.

What should I ask before booking Eye Rejuran in Korea?

  • Is my main finding texture, pigment, visible vessels, hollowing or swelling, and how did you decide?
  • Which sealed product will you open, and is anything mixed with it?
  • Will you treat the eye area only or the whole face, and by hand or with an injector?
  • What pain control do you plan, and what should I expect to feel and see afterward?
  • Do my allergies, medications, medical conditions or past eyelid procedures rule this out under the current label?
  • When will we judge the result, and what would make you stop the series?
  • Who do I contact after I fly home, and which symptoms need emergency care?

A physician's responsibility in this decision is to show you the whole picture, including the limits of the evidence and the reasons not to treat. The decision stays with you, and you should have these facts before you make it.

Tune Clinic Apgujeong today: the lobby, waiting areas and treatment rooms where consultations and treatments take place.

Reception desk and lounge seating in the main lobby
Quiet waiting nook with a long upholstered bench
Corridor of treatment rooms with privacy curtains
Treatment room with two beds and a device cart
Procedure chair with a second device room beyond
Washbasin with a backlit mirror

Sources

  1. PharmaResearch / idsMED. REJURAN Doctor Brochure. 2024. Product composition, lower viscosity of Rejuran i, stated positioning. Commercial literature.
  2. Comparison of the effects of polynucleotide and hyaluronic acid fillers on periocular rejuvenation, a randomized, double-blind, split-face trial. Journal of Dermatological Treatment 2022. 27-participant eye-area trial, three treatments two weeks apart, no significant between-group difference in subjective scores or dermal density.
  3. Efficacy of Ionization-Adjusted PN Filler in Minimizing Injection Pain, a randomized, patient-blinded, split-face study. Aesthetic Plastic Surgery 2025. 15-participant study documenting injection pain and local reactions with conventional Rejuran i.
  4. Polynucleotides (PN/PDRN) in regenerative aesthetic medicine, narrative review. Revista de la Sociedad Espanola de Medicina Estetica 2026. Mechanism largely preclinical, mixed terminology, limited transfer of evidence across formulations and routes.
  5. K Bridge Medical / REJURAN ANZ. FAQs. Accessed 2026. Acknowledged temporary skin reactions and individualized planning. Commercial source.
  6. Efficacy of Polynucleotides in Periorbital Rejuvenation, a systematic review. Aesthetic Surgery Journal Open Forum 2026. Includes a trial retracted in March 2026, so its totals are not used here.
  7. Notice of Retraction, PN versus HA crow's-feet trial. Journal of Korean Medical Science 2016. Retraction for incorrect funding and conflict-of-interest disclosure.
  8. Retraction, study comparing polycaprolactone and polynucleotide fillers for crow's feet. Journal of Cosmetic Dermatology 2026. March 16, 2026 retraction after the comparator material was misidentified.
  9. Polynucleotides for Facial Erythema and Skin Barrier Repair in Adult Atopic Dermatitis, a pilot study. Dermatologic Therapy 2026. Uncontrolled pilot in 19 adults, no significant melanin-index change.
  10. Korean National Law Information Center. Medical Service Act, Article 56. 2026. Korean medical advertising restrictions.
  11. Therapeutic Goods Administration. REJURAN, dermal tissue reconstructive material, animal-derived, ARTG 412630. 2023. Australian register entry, Class III, animal-derived material.
  12. PharmaResearch. Corporate history. Undated. Manufacturer report of CE MDR certification for three Rejuran products.
  13. United States FDA. FDA-Approved Dermal Fillers. Accessed 2026. No Rejuran entry seen on the approval reference page.
  14. United States FDA. Dermal Fillers (Soft Tissue Fillers). Accessed 2026. General injectable safety context and symptoms that need immediate care.
  15. RealSelf. Are Polynucleotides safe for under-eye wrinkles? 2026. Clinician opinion separating skin quality from structural hollowing.
  16. American Academy of Dermatology. Dermatologists' top tips for relieving dry skin. Accessed 2026. Conservative dry-skin care and cold, dry weather.
  17. American Academy of Ophthalmology EyeWiki. Periorbital Polynucleotide Injections. 2026. Eye-area safety and screening context, including fish and shellfish allergy. Educational page, not a guideline.
  18. Japan Ministry of Health, Labour and Welfare. Recall summary, Rejuran HM Serum and WM Serum. 2021. Cosmetic packaging recall, not an injectable recall.
  19. PharmaResearch / Rejuran. Rejuran domestic instructions for use, DB0229(02). December 2024. Korean instructions for use, document dated December 2024, device permit 14-825. Contraindications include non-resorbable or recent filler at the site, NSAIDs, antiplatelet agents, anticoagulants and immunosuppressants, allergic disease, autoimmune disease, sarcoid granulomatous pathology, Osler's endocarditis, hypersensitivity to polynucleotide sodium, pregnancy or breastfeeding, minors, and inflamed or infected skin. Verified 2026-11-12 against the full PDF.
  20. Periorbital Hyperpigmentation, a comprehensive review. Journal of Clinical and Aesthetic Dermatology 2016. Pigmentary, vascular, structural and mixed causes of dark circles.
WhatsAppCheck available dates

Dr. Ju replies in English, usually within a few hours during clinic hours (KST).

Patient information

This is patient information published by Tune Clinic. It is not medical advice and does not replace a consultation. Treatment suitability is decided in person, outcomes vary by individual, and some patients are advised that none of the treatments described here is right for them.

Photographed at Tune

The people behind your plan.

Drag to explore · open a photograph to see it in full
Physician assessing facial structure
Your face, assessed in person.
Physician and patient reviewing the plan with a mirror
A plan you can discuss together.
Skin analysis at Tune Clinic
A closer look at your skin.
Physician explaining a facial assessment
Time to ask your questions.
A conversation first

Free consultation. Decide on treatment after your assessment.

Direct clinic contact

English consultation and follow-up in the same conversation.

Read patient reviews ↗On Google · international and local patients